Democrats are showing little interest in cooperating with the Republicans who control Congress on legislation to dismantle the Obamacare health insurance law, but some are signaling a willingness to collaborate on action to curb rising drug prices.
An article published on Seeking Alpha outlining a Chinese bribery verdict against SinoVac’s chief executive officer has sparked two U.S. law firms to announce an investigation concerning possible violations of federal securities laws by the Chinese company on behalf of shareholders.
Grappling with allegations of improper sales practices, Alexion Pharmaceuticals has announced a failure of a Phase II/III trial for expanded use of Soliris.
The end of 2016 appears to have at least one more unpredictable story – who is going to buy Swiss-based Actelion Pharmaceuticals?
OvaScience, a fertility-focused bitotech, will undergo a corporate restructuring that is resulting in the termination of 30 percent of its workforce and causing the resignation of the company’s chief executive and chief operations officers.
India’s largest drugmaker, Sun Pharmaceutical Industries, is buying the skin cancer drug Odomzo from Switzerland-based Novartis for $175 million upfront.
It’s expected that a large number of clinical trials will result in failure. 2016 saw numerous trial failures, but analysts at The Motley Fool selected seven failures that are expected to have a direct impact on the forward outlooks of the companies involved.
Roche Holding AG’s emicizumab drug for treating hemophilia A showed it worked in a phase III study, the Swiss drugmaker said.
Roughly 6.4 million consumers signed up for Obamacare insurance on Healthcare.gov from Nov. 1 to Dec. 19, 2016, indicating “clear demand for quality, affordable coverage,” the U.S. government said.
The surprise selection of Michel Vounatsos to run Biogen Inc. signals a shift toward a more commercial management focus after years of targeting ambitious scientific gains, and likely keeps the U.S. biotech in play as a takeover target.